GLP-1 for Teens: Wegovy for Adolescents

GLP-1 for teens has moved from off-label improvisation to formal approval: Wegovy (semaglutide) is FDA-approved for chronic weight management in adolescents aged 12 and older with obesity, and Saxenda (liraglutide) carries the same age clearance. That change followed real trial evidence in young people, most prominently the STEP TEENS study of semaglutide, and it sits alongside a shift in how pediatric medicine frames obesity: not as a failure of willpower in a child, but as a chronic condition with biological drivers that sometimes warrants medical treatment. This guide lays out what the approvals actually cover, what the teen trials showed, who qualifies, the side effect picture in adolescents, and the genuine controversy, without overselling the medication or dismissing the concerns.

Why pediatric obesity is treated as a medical condition

For a long time, weight in children was treated almost entirely as a behavioral matter: eat less, move more, and the problem resolves. The data did not cooperate. Lifestyle programs, even intensive and well-run ones, produce modest average weight change in adolescents with established obesity, and the effect often fades once the program ends. The reason is the same biology that operates in adults. The body defends a higher weight through hunger and satiety hormones, and that defense does not switch off because the person is fifteen rather than fifty. Appetite regulation is largely involuntary, a point covered in our piece on realistic weight loss goals on GLP-1.

In 2023 the American Academy of Pediatrics (AAP) published clinical practice guidelines that formalized this shift. The guidelines recommend that clinicians offer adolescents 12 and older with obesity pharmacotherapy as an adjunct to intensive health behavior and lifestyle treatment, and that they evaluate teens 13 and older with severe obesity for metabolic and bariatric surgery. The headline principle was a move away from "watchful waiting," the older habit of delaying treatment in the hope a child would grow into their weight. The AAP framed untreated obesity as carrying real, measurable risk that accumulates over time, and argued that withholding effective treatment is itself a decision with consequences.

Those risks are not abstract. Adolescent obesity tracks strongly into adulthood, and it is associated with type 2 diabetes appearing in the teen years, high blood pressure, fatty liver disease, obstructive sleep apnea, joint problems, and the social and psychological burden of weight stigma. The case for treating it as a medical condition rests on this: the condition is biologically driven, it is persistent, and left alone it tends to worsen rather than resolve on its own.

What the teen trial evidence shows

The pivotal study for semaglutide in this age group was STEP TEENS, published in the New England Journal of Medicine in 2022. It enrolled adolescents aged 12 to under 18 with obesity, randomized them to once-weekly semaglutide at the 2.4 mg dose or placebo, and gave both groups lifestyle support. The results were substantial. Adolescents on semaglutide saw a mean reduction in BMI of roughly 16 percent over 68 weeks, while the placebo group saw a slight increase. A large majority of the treated teens lost a clinically meaningful amount of weight, and many crossed below the obesity threshold entirely. Improvements also showed up in waist circumference and several cardiometabolic markers.

To put that in context, the adult semaglutide trial, STEP 1, reported by Wilding and colleagues in 2021, found mean weight loss of around 15 percent over a similar period. The adolescent result was in the same range, which is notable: the medication appears to work in teens about as well as it does in adults, rather than being a watered-down effect. Liraglutide, the daily injectable sold as Saxenda, was studied separately in adolescents and produced more modest weight change, consistent with its smaller effect in adults, but enough to earn its own pediatric approval.

It is worth being precise about what these trials did and did not establish. They measured weight and metabolic change over roughly a year to eighteen months. They were not designed to measure outcomes a decade later, and they cannot, because the medications are too new for that data to exist. The mechanism by which semaglutide produces these effects, by acting on appetite and satiety signaling, is the same in adolescents as in adults and is explained in how semaglutide works for weight loss and in our overview, semaglutide explained.

Who qualifies

The approvals are specific. Wegovy and Saxenda are cleared for adolescents aged 12 and older, and eligibility is defined by BMI percentile rather than the absolute BMI numbers used for adults. Because children are still growing, a raw BMI is meaningless without reference to age and sex, so pediatric obesity is defined against growth charts. A teen at or above the 95th percentile for their age and sex meets the definition of obesity that the labels use as the entry point. This percentile framing is the main thing that distinguishes teen eligibility from the adult criteria described in who qualifies for a GLP-1 prescription.

Factor	Adults	Adolescents (12 to 17)
Approved GLP-1 products for weight	Wegovy, Zepbound, Saxenda	Wegovy and Saxenda (semaglutide and liraglutide)
Eligibility threshold	BMI of 30, or 27 with a weight-related condition	Obesity by BMI percentile (at or above the 95th percentile for age and sex)
Minimum age	18	12
Required context	Alongside diet and activity	Alongside lifestyle support and a pediatric clinician
Headline trial	STEP 1 (semaglutide), SURMOUNT-1 (tirzepatide)	STEP TEENS (semaglutide)
Long-term data	Several years and accumulating	Limited, still accumulating

One product worth naming for clarity: Zepbound (tirzepatide), the dual agonist that produces the largest average weight loss in adults, is not currently approved for adolescents. The teen approvals at this point cover semaglutide and liraglutide. That distinction matters, because the brand a teen might be eligible for is not simply the one with the biggest headline numbers in adult studies.

Eligibility is also more than a number. A responsible pediatric clinician will look at the whole picture: the teen's weight trajectory, any weight-related conditions already present, their psychological readiness, the family context, and whether intensive lifestyle support is genuinely in place. Pharmacotherapy in this age group is meant to be an addition to that support, not a replacement for it.

Safety and side effects in teens

The side effect profile in adolescents closely mirrors what is seen in adults, and it is dominated by the gastrointestinal tract. Nausea, vomiting, diarrhea, and constipation are the common complaints, and they cluster in the early weeks and during each dose increase. For most teens these effects are mild to moderate and ease as the body adjusts, which is exactly why the dose is escalated slowly over months rather than started high. The general arc of these effects is mapped in our GLP-1 side effects timeline, and the pattern holds for younger patients.

In STEP TEENS, gastrointestinal events were the most frequently reported adverse effects, more common in the semaglutide group than in placebo, and they were the main reason a small number of participants stopped treatment. Gallbladder-related problems, which can follow rapid weight loss of any kind, were noted as well. There were no new safety signals unique to adolescents that did not appear in adult studies, which was a reassuring finding as far as it went.

The honest caveat is duration. Long-term safety data in adolescents is still accumulating, simply because these medications have not been used in this population long enough to generate it. Several questions remain genuinely open: the effects of years of use during a period of active growth and development, what happens to weight when the medication is stopped (adult data show regain is common, and there is no reason to expect teens differ), and whether sustained appetite suppression has any bearing on adequate nutrition during adolescence. These are not reasons for alarm, but they are reasons for ongoing clinical supervision rather than a set-and-forget prescription. Standard contraindications also apply, including a personal or family history of medullary thyroid carcinoma, and any GLP-1 in this age group requires a licensed clinician and, in practice, parental involvement.

The controversy, fairly stated

This is a topic where reasonable people disagree, and the disagreement deserves to be represented honestly rather than flattened to one side. The case against reaching for medication centers on a few real concerns. One is the discomfort of prescribing a drug that, on current evidence, is likely to be needed long-term to a person who is still developing. Another is the worry that medication could crowd out or undermine the development of eating and activity habits. A third is the influence of weight stigma running the other way: that prescribing reflects a culture too quick to medicalize bodies, and that some teens flagged by BMI percentile are healthy. There is also unease about marketing pressure and about access flowing to those who can pay rather than those at highest medical risk.

The counterargument is equally grounded. Untreated obesity in adolescence is not a neutral baseline; it carries documented risk that compounds over time, including type 2 diabetes, liver disease, and cardiovascular harm, plus the heavy psychological toll of stigma that withholding treatment does nothing to relieve. The "let them grow out of it" expectation is contradicted by the data, since adolescent obesity usually persists into adulthood. Framed this way, declining to treat is not the cautious, neutral choice it can appear to be; it is a choice with its own risks. The medication, used appropriately, is a tool to reduce a real disease burden, not a shortcut or a cosmetic intervention.

The reconciliation most clinicians reach is that neither blanket enthusiasm nor blanket refusal is right. The decision belongs to a specific teen, their family, and a pediatric clinician who knows the case, weighing that individual's risk against the medication's benefits and uncertainties. The framing of obesity as a chronic condition, addressed in realistic weight loss goals on GLP-1, applies as much to adolescents as to adults: it is managed, not cured, and the medication is one part of that management.

Always alongside lifestyle and a clinician

Every approval, every guideline, and every trial places these medications as an adjunct, a word that matters. The teens in STEP TEENS received lifestyle support as well as the drug; the AAP guidelines describe pharmacotherapy as an addition to intensive health behavior treatment, not a substitute. In practice this means nutrition guidance, physical activity, attention to sleep and mental health, and family involvement continue alongside the prescription. The medication makes the behavioral changes more achievable by quieting the relentless hunger that defeats them, rather than replacing the need for them.

It also means real medical oversight. A pediatric clinician should be assessing growth, monitoring for side effects, checking that nutrition stays adequate, and reassessing periodically whether the medication is doing what was intended. Prescription GLP-1 medications require a licensed clinician in any case, and in adolescents that supervision is doubly important given the developmental stage and the thinner long-term evidence base. This is not a class of drug for casual or unsupervised use at any age, and least of all in a twelve-to-seventeen-year-old.